BIOMAT Database Logo BIOMAT Database Logo

Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis. 2007

Luciano Potena, and Cecile T J Holweg, and Marcy L Vana, and Leena Bashyam, and Jaya Rajamani, and A Louise McCormick, and John P Cooke, and Hannah A Valantine, and Edward S Mocarski
Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

Despite antiviral prophylaxis, a high percentage (over 90%) of heart transplant patients experience active cytomegalovirus (CMV) infection, diagnosed by detection of viral DNA in peripheral blood polymorphonuclear leukocytes within the first few months posttransplantation. Viral DNA was detected in mononuclear cells prior to detection in granulocytes from CMV-seropositive recipients (R+) receiving a heart from a CMV-seropositive donor (D+). Based on assessment of systemic infection in leukocyte populations, both R+ subgroups (R+/D- and R+/D+) experienced a greater infection burden than the R-/D+ subgroup, which was aggressively treated because of a higher risk of acute CMV disease. Despite widespread systemic infection in all at-risk patient subgroups, CMV DNA was rarely (< 3% of patients) detected in transplanted heart biopsy specimens. The R+ patients more frequently exceeded the 75th percentile of the CMV DNA copy number distribution in leukocytes (110 copies/10(5) polymorphonuclear leukocytes) than the R-/D+ subgroup. Therefore, active systemic CMV infection involving leukocytes is common in heart transplant recipients receiving prophylaxis to reduce acute disease. Infection of the transplanted organ is rare, suggesting that chronic vascular disease attributed to CMV may be driven by the consequences of systemic infection.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

Luciano Potena, and Cecile T J Holweg, and Marcy L Vana, and Leena Bashyam, and Jaya Rajamani, and A Louise McCormick, and John P Cooke, and Hannah A Valantine, and Edward S Mocarski
Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis.
November 2004, Transplantation,
Luciano Potena, and Cecile T J Holweg, and Marcy L Vana, and Leena Bashyam, and Jaya Rajamani, and A Louise McCormick, and John P Cooke, and Hannah A Valantine, and Edward S Mocarski
Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis.
June 2023, JHEP reports : innovation in hepatology,
Luciano Potena, and Cecile T J Holweg, and Marcy L Vana, and Leena Bashyam, and Jaya Rajamani, and A Louise McCormick, and John P Cooke, and Hannah A Valantine, and Edward S Mocarski
Role of antiviral prophylaxis in renal transplant recipients at high risk of cytomegalovirus infection.
July 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Luciano Potena, and Cecile T J Holweg, and Marcy L Vana, and Leena Bashyam, and Jaya Rajamani, and A Louise McCormick, and John P Cooke, and Hannah A Valantine, and Edward S Mocarski
Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.
June 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Luciano Potena, and Cecile T J Holweg, and Marcy L Vana, and Leena Bashyam, and Jaya Rajamani, and A Louise McCormick, and John P Cooke, and Hannah A Valantine, and Edward S Mocarski
Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.
September 2011, Transplant international : official journal of the European Society for Organ Transplantation,
Luciano Potena, and Cecile T J Holweg, and Marcy L Vana, and Leena Bashyam, and Jaya Rajamani, and A Louise McCormick, and John P Cooke, and Hannah A Valantine, and Edward S Mocarski
Preemptive Therapy vs Antiviral Prophylaxis in Cytomegalovirus-Seronegative Liver Transplant Recipients With Seropositive Donors.
September 2020, JAMA,
Luciano Potena, and Cecile T J Holweg, and Marcy L Vana, and Leena Bashyam, and Jaya Rajamani, and A Louise McCormick, and John P Cooke, and Hannah A Valantine, and Edward S Mocarski
Cytomegalovirus prophylaxis in kidney transplant recipients.
December 1995, ANNA journal,
Luciano Potena, and Cecile T J Holweg, and Marcy L Vana, and Leena Bashyam, and Jaya Rajamani, and A Louise McCormick, and John P Cooke, and Hannah A Valantine, and Edward S Mocarski
Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis.
June 2006, Transplantation,
Luciano Potena, and Cecile T J Holweg, and Marcy L Vana, and Leena Bashyam, and Jaya Rajamani, and A Louise McCormick, and John P Cooke, and Hannah A Valantine, and Edward S Mocarski
The burden of cytomegalovirus infection remains high in high-risk kidney transplant recipients despite six-month valganciclovir prophylaxis.
August 2021, Transplant infectious disease : an official journal of the Transplantation Society,
Luciano Potena, and Cecile T J Holweg, and Marcy L Vana, and Leena Bashyam, and Jaya Rajamani, and A Louise McCormick, and John P Cooke, and Hannah A Valantine, and Edward S Mocarski
Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
November 2010, Transplantation,
Copied contents to your clipboard!